Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia
作者： Marco Falcone , Pierluigi Viale , Giusy Tiseo , Manjunath Pai
DOI: 10.1080/17425255.2018.1434142
关键词:
摘要: Introduction: Ceftazidime-avibactam (CAZ-AVI) is a combination of third-generation cephalosporin and non-β-lactam, β-lactamase inhibitor, recently approved for urinary tract infections ...
core.ac.uk 
sci-hub.se 参考文章(44)
M. J. Melchers, E. Mavridou, S. Seyedmousavi, A. C. van Mil, C. Lagarde, J. W. Mouton, Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice Antimicrobial Agents and Chemotherapy. ,vol. 59, pp. 3373- 3376 ,(2015) , 10.1128/AAC.04402-14
Lauren E Arthur, Russell S Kizor, Adrian G Selim, Mieke L van Driel, Leonardo Seoane, Antibiotics for ventilator-associated pneumonia. Cochrane Database of Systematic Reviews. ,vol. 10, pp. 1- ,(2016) , 10.1002/14651858.CD004267.PUB4
Emmanuel Boselli, Dominique Breilh, Thomas Rimmelé, Christian Guillaume, Fabien Xuereb, Marie-Claude Saux, Lionel Bouvet, Dominique Chassard, Bernard Allaouchiche, Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Critical Care Medicine. ,vol. 36, pp. 1500- 1506 ,(2008) , 10.1097/CCM.0B013E318170BA21
Marisa L. Winkler, Krisztina M. Papp-Wallace, Andrea M. Hujer, T. Nicholas Domitrovic, Kristine M. Hujer, Kelly N. Hurless, Marion Tuohy, Geraldine Hall, Robert A. Bonomo, Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. ,vol. 59, pp. 1020- 1029 ,(2015) , 10.1128/AAC.04238-14
Anton Y. Peleg, David C. Hooper, Hospital-Acquired Infections Due to Gram-Negative Bacteria The New England Journal of Medicine. ,vol. 362, pp. 1804- 1813 ,(2010) , 10.1056/NEJMRA0904124
D.M. Richards, R.N. Brogden, Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. ,vol. 29, pp. 105- 161 ,(1985) , 10.2165/00003495-198529020-00002
Emmanuel Boselli, Dominique Breilh, Thomas Rimmelé, Jean-Charles Poupelin, Marie-Claude Saux, Dominique Chassard, Bernard Allaouchiche, Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia Intensive Care Medicine. ,vol. 30, pp. 989- 991 ,(2004) , 10.1007/S00134-004-2171-2
Nobumitsu Tominaga, Timi Edeki, James Li, Maria Learoyd, M René Bouw, Shampa Das, None, Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy. ,vol. 21, pp. 551- 558 ,(2015) , 10.1016/J.JIAC.2015.04.006
Henri Merdjan, Manickam Rangaraju, Antoine Tarral, Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies Clinical Drug Investigation. ,vol. 35, pp. 307- 317 ,(2015) , 10.1007/S40261-015-0283-9
José A. Vazquez, Luis Demetrio González Patzán, David Stricklin, Dipesh D. Duttaroy, Zouheir Kreidly, Joy Lipka, Carole Sable, Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study Current Medical Research and Opinion. ,vol. 28, pp. 1921- 1931 ,(2012) , 10.1185/03007995.2012.748653